Lantern Pharma Inc (LTRN)
Lantern Pharma Inc. is a biotechnology company focused on oncology drug discovery and development, with its common stock listed on NASDAQ under the ticker LTRN. The company’s pipeline includes LP-300, a phase 2 candidate being studied in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, a phase 1 candidate being evaluated across several solid tumors, including pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system cancers; and LP-284, a phase 1 candidate in development for non-Hodgkin’s lymphomas such as mantle cell lymphoma and double hit lymphoma. Lantern Pharma is also advancing STAR-001 in preclinical development for glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and select rare pediatric CNS cancers. In addition, it has an ADC program and collaborations with Oregon Therapeutics, TTC Oncology, and Actuate Therapeutics to support selected oncology programs.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LTRN
|
$3.62
|
25.3% Upside
|
Undervalued
|
$20
|
592.0% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-2.3x
|
10.8x
|
—
|
37.639 M
|
30.865 M
|
0.2%
|
84.8%
|
-19.8
|
—
|
94.7%
|
